Nils-Göran Pettersson
Presidente en Mobidag Sverige AB .
Relaciones activas
Nombre | Sexo | Edad | Empresas relacionadas | Colaboración |
---|---|---|---|---|
Gustav Ingemar Kihlström | M | 71 |
OxyPharma AB
G. Pettersson & Partners AB
Axelar AB
Axelar AB BiotechnologyHealth Technology Axelar AB operates as a biotechnology company. It aims to develop novel efficacious anti-cancer treatments. The company was founded by Erik Gustav Magnus Axelson and Lars Olov Larsson in 2003 and is headquartered in Solna, Sweden. | 23 años |
Mårten Österlund | M | 67 | 25 años | |
Tuomas Tenkanen | M | 63 |
Mobidiag Oy
Mobidiag Oy Miscellaneous Commercial ServicesCommercial Services Mobidiag Oy provides molecular diagnostic for infectious diseases. It develops and provides microarray-based Prove-it technology for early and diagnosis of life-threatening pathogenic microbes causing severe infections. Its Amplidiag product line comprises products for gastrointestinal pathogens and utilizes quantitative real-time polymerase chain reaction technology. The company was founded by Mart Saarma in 2000 and is headquartered in Espoo, Finland. | 11 años |
Jonas Göran Ekblom | M | 59 |
Pergamum AB
Pergamum AB Pharmaceuticals: MajorHealth Technology Pergamum AB develops, registers, markets, and trades pharmaceutical products based on therapeutic peptides. The company was founded on June 18, 2008 and is headquartered in Solna, Sweden. | 14 años |
Fredrik Öberg | M | 59 | 13 años | |
Carl-Johan Blomberg | M | 72 |
Pfizer Pension Trust Sweden
| - |
Stuart Cranmer | M | - |
Mobidiag Oy
Mobidiag Oy Miscellaneous Commercial ServicesCommercial Services Mobidiag Oy provides molecular diagnostic for infectious diseases. It develops and provides microarray-based Prove-it technology for early and diagnosis of life-threatening pathogenic microbes causing severe infections. Its Amplidiag product line comprises products for gastrointestinal pathogens and utilizes quantitative real-time polymerase chain reaction technology. The company was founded by Mart Saarma in 2000 and is headquartered in Espoo, Finland. | - |
Joe Bernardo | M | - |
Mobidiag Oy
Mobidiag Oy Miscellaneous Commercial ServicesCommercial Services Mobidiag Oy provides molecular diagnostic for infectious diseases. It develops and provides microarray-based Prove-it technology for early and diagnosis of life-threatening pathogenic microbes causing severe infections. Its Amplidiag product line comprises products for gastrointestinal pathogens and utilizes quantitative real-time polymerase chain reaction technology. The company was founded by Mart Saarma in 2000 and is headquartered in Espoo, Finland. | - |
Feng Chaojie | F | - |
Mobidiag Oy
Mobidiag Oy Miscellaneous Commercial ServicesCommercial Services Mobidiag Oy provides molecular diagnostic for infectious diseases. It develops and provides microarray-based Prove-it technology for early and diagnosis of life-threatening pathogenic microbes causing severe infections. Its Amplidiag product line comprises products for gastrointestinal pathogens and utilizes quantitative real-time polymerase chain reaction technology. The company was founded by Mart Saarma in 2000 and is headquartered in Espoo, Finland. | - |
Jean-François Hilaire | M | 60 | 9 años | |
Jean de Gunzburg | M | - |
Mobidiag Oy
Mobidiag Oy Miscellaneous Commercial ServicesCommercial Services Mobidiag Oy provides molecular diagnostic for infectious diseases. It develops and provides microarray-based Prove-it technology for early and diagnosis of life-threatening pathogenic microbes causing severe infections. Its Amplidiag product line comprises products for gastrointestinal pathogens and utilizes quantitative real-time polymerase chain reaction technology. The company was founded by Mart Saarma in 2000 and is headquartered in Espoo, Finland. | - |
Torsten Rüdiger Goesch | M | 65 |
Pergamum AB
Pergamum AB Pharmaceuticals: MajorHealth Technology Pergamum AB develops, registers, markets, and trades pharmaceutical products based on therapeutic peptides. The company was founded on June 18, 2008 and is headquartered in Solna, Sweden. | - |
Mark Royston Quick | M | 58 | 18 años | |
Margit Mahlapuu | M | 52 |
Pergamum AB
Pergamum AB Pharmaceuticals: MajorHealth Technology Pergamum AB develops, registers, markets, and trades pharmaceutical products based on therapeutic peptides. The company was founded on June 18, 2008 and is headquartered in Solna, Sweden. | - |
Hannu Tapani Syrjälä | M | 58 |
Mobidiag Oy
Mobidiag Oy Miscellaneous Commercial ServicesCommercial Services Mobidiag Oy provides molecular diagnostic for infectious diseases. It develops and provides microarray-based Prove-it technology for early and diagnosis of life-threatening pathogenic microbes causing severe infections. Its Amplidiag product line comprises products for gastrointestinal pathogens and utilizes quantitative real-time polymerase chain reaction technology. The company was founded by Mart Saarma in 2000 and is headquartered in Espoo, Finland. | 7 años |
Göran Harald Linder | M | 62 |
Pergamum AB
Pergamum AB Pharmaceuticals: MajorHealth Technology Pergamum AB develops, registers, markets, and trades pharmaceutical products based on therapeutic peptides. The company was founded on June 18, 2008 and is headquartered in Solna, Sweden. | - |
Bengt Gerdin | M | 77 |
OxyPharma AB
| 21 años |
Rabbe Ilari Klemets | M | - |
Mobidiag Oy
Mobidiag Oy Miscellaneous Commercial ServicesCommercial Services Mobidiag Oy provides molecular diagnostic for infectious diseases. It develops and provides microarray-based Prove-it technology for early and diagnosis of life-threatening pathogenic microbes causing severe infections. Its Amplidiag product line comprises products for gastrointestinal pathogens and utilizes quantitative real-time polymerase chain reaction technology. The company was founded by Mart Saarma in 2000 and is headquartered in Espoo, Finland. | - |
Bernard Pluta | M | - | 9 años |
Gráfico relacional
Relaciones con varias empresas
Antiguas relaciones
Nombre | Sexo | Edad | Empresas relacionadas | Colaboración |
---|---|---|---|---|
Maris Gunars Hartmanis | M | 71 | 3 años | |
Rolf Classon | M | 79 |
Swedish Orphan International Holding AB
Swedish Orphan International Holding AB Pharmaceuticals: MajorHealth Technology Swedish Orphan International Holding AB is an international group with its head office in Stockholm, Sweden. The original company was formed in 1988, taking as its starting point the US Orphan Drug Act of 1983. In 2004, the company was acquired by a consortium consisting of Investor Growth Capital, Skandia Investment and the management of Swedish Orphan International AB. The operating companies are Swedish Orphan International and its subsidiaries in Europe and Japan. The organizational structure is primarily based on a logistical perspective. In order to reach patients in emergency situations, regardless of where they are, it needs an extensive organization with strong local roots and the ability to see things in a larger perspective. The better and broader its partnerships, the more effectively the firm can work and the greater the synergies that it can achieve between the various markets. | 6 años |
Nils Bert Åke Eriksson | M | 80 | 16 años | |
Niklas Prager | M | 54 | 3 años | |
Edith Olga Elisabeth Lindner | F | 68 | 3 años | |
Anders O. Lönner | M | 79 | 14 años | |
Karl Axel Christer Lindberg | M | 76 | 1 años | |
Carlos von Bonhorst | M | 67 | - | |
Per Olof Kjell Johansson | M | 68 | - | |
Marianne Dicander Alexandersson | F | 65 | - | |
Gert Lennart Perlhagen | M | 81 | 7 años | |
Ronald Eric Long | M | 77 | 4 años | |
Jane M. Birgitta Stymne Göransson | F | 67 | 3 años | |
Charlotte Elisabet Edenius | M | 66 | 5 años | |
Wenche Nelly A. Rolfsen Sandsborg | M | 72 | 3 años | |
Joan Teresa Traynor | F | 65 | 2 años | |
Björn Westberg | M | 62 | 10 años | |
Bo Jesper Hansen | M | 66 |
Swedish Orphan International Holding AB
Swedish Orphan International Holding AB Pharmaceuticals: MajorHealth Technology Swedish Orphan International Holding AB is an international group with its head office in Stockholm, Sweden. The original company was formed in 1988, taking as its starting point the US Orphan Drug Act of 1983. In 2004, the company was acquired by a consortium consisting of Investor Growth Capital, Skandia Investment and the management of Swedish Orphan International AB. The operating companies are Swedish Orphan International and its subsidiaries in Europe and Japan. The organizational structure is primarily based on a logistical perspective. In order to reach patients in emergency situations, regardless of where they are, it needs an extensive organization with strong local roots and the ability to see things in a larger perspective. The better and broader its partnerships, the more effectively the firm can work and the greater the synergies that it can achieve between the various markets. | 16 años |
Björn C. Andersson | M | 78 | - | |
Lars Ivar Robert Adlersson | M | 60 | - | |
Susana Ayesa Alvarez | M | 54 | 3 años | |
Anders R. Hallberg | M | 79 | 7 años | |
Henric Juserius | M | 61 | - | |
Richard Bethell | M | 61 | - | |
Henrik Krook | M | 51 | - | |
Magnus Renck | M | 71 | - | |
Lennart Quist | M | 66 | - | |
Alf Gunnar Martin Nicklasson | M | 69 |
Swedish Orphan International Holding AB
Swedish Orphan International Holding AB Pharmaceuticals: MajorHealth Technology Swedish Orphan International Holding AB is an international group with its head office in Stockholm, Sweden. The original company was formed in 1988, taking as its starting point the US Orphan Drug Act of 1983. In 2004, the company was acquired by a consortium consisting of Investor Growth Capital, Skandia Investment and the management of Swedish Orphan International AB. The operating companies are Swedish Orphan International and its subsidiaries in Europe and Japan. The organizational structure is primarily based on a logistical perspective. In order to reach patients in emergency situations, regardless of where they are, it needs an extensive organization with strong local roots and the ability to see things in a larger perspective. The better and broader its partnerships, the more effectively the firm can work and the greater the synergies that it can achieve between the various markets. | 3 años |
Maria Klockare | F | - |
Axelar AB
Axelar AB BiotechnologyHealth Technology Axelar AB operates as a biotechnology company. It aims to develop novel efficacious anti-cancer treatments. The company was founded by Erik Gustav Magnus Axelson and Lars Olov Larsson in 2003 and is headquartered in Solna, Sweden. | 6 años |
Erik Haeffler | M | 57 | 6 años | |
Thomas Beck | M | - | 6 años | |
Ulf Björklund | M | 68 |
OxyPharma AB
| 8 años |
John Öhd | M | 53 | 4 años | |
Maria Engström | F | 52 | 2 años | |
Stina Lundgren | M | 45 | - | |
Aaron Small | M | - | 9 años | |
Erik Domines | M | 60 | 4 años | |
Carlos von Bonhorst | M | - | 6 años | |
Jan Anders Vedin | M | 82 | - | |
Anna Styrud | F | 63 | - | |
Kerstin Annas | F | 54 | - | |
Mats Blom | M | 59 |
Swedish Orphan International Holding AB
Swedish Orphan International Holding AB Pharmaceuticals: MajorHealth Technology Swedish Orphan International Holding AB is an international group with its head office in Stockholm, Sweden. The original company was formed in 1988, taking as its starting point the US Orphan Drug Act of 1983. In 2004, the company was acquired by a consortium consisting of Investor Growth Capital, Skandia Investment and the management of Swedish Orphan International AB. The operating companies are Swedish Orphan International and its subsidiaries in Europe and Japan. The organizational structure is primarily based on a logistical perspective. In order to reach patients in emergency situations, regardless of where they are, it needs an extensive organization with strong local roots and the ability to see things in a larger perspective. The better and broader its partnerships, the more effectively the firm can work and the greater the synergies that it can achieve between the various markets. | 3 años |
Thomas Lennart Eklund | M | 57 |
Swedish Orphan International Holding AB
Swedish Orphan International Holding AB Pharmaceuticals: MajorHealth Technology Swedish Orphan International Holding AB is an international group with its head office in Stockholm, Sweden. The original company was formed in 1988, taking as its starting point the US Orphan Drug Act of 1983. In 2004, the company was acquired by a consortium consisting of Investor Growth Capital, Skandia Investment and the management of Swedish Orphan International AB. The operating companies are Swedish Orphan International and its subsidiaries in Europe and Japan. The organizational structure is primarily based on a logistical perspective. In order to reach patients in emergency situations, regardless of where they are, it needs an extensive organization with strong local roots and the ability to see things in a larger perspective. The better and broader its partnerships, the more effectively the firm can work and the greater the synergies that it can achieve between the various markets. | 6 años |
Göran Arvidson | M | 64 |
Swedish Orphan International Holding AB
Swedish Orphan International Holding AB Pharmaceuticals: MajorHealth Technology Swedish Orphan International Holding AB is an international group with its head office in Stockholm, Sweden. The original company was formed in 1988, taking as its starting point the US Orphan Drug Act of 1983. In 2004, the company was acquired by a consortium consisting of Investor Growth Capital, Skandia Investment and the management of Swedish Orphan International AB. The operating companies are Swedish Orphan International and its subsidiaries in Europe and Japan. The organizational structure is primarily based on a logistical perspective. In order to reach patients in emergency situations, regardless of where they are, it needs an extensive organization with strong local roots and the ability to see things in a larger perspective. The better and broader its partnerships, the more effectively the firm can work and the greater the synergies that it can achieve between the various markets. | - |
Lena Louise Nilsson | F | 57 |
Swedish Orphan International Holding AB
Swedish Orphan International Holding AB Pharmaceuticals: MajorHealth Technology Swedish Orphan International Holding AB is an international group with its head office in Stockholm, Sweden. The original company was formed in 1988, taking as its starting point the US Orphan Drug Act of 1983. In 2004, the company was acquired by a consortium consisting of Investor Growth Capital, Skandia Investment and the management of Swedish Orphan International AB. The operating companies are Swedish Orphan International and its subsidiaries in Europe and Japan. The organizational structure is primarily based on a logistical perspective. In order to reach patients in emergency situations, regardless of where they are, it needs an extensive organization with strong local roots and the ability to see things in a larger perspective. The better and broader its partnerships, the more effectively the firm can work and the greater the synergies that it can achieve between the various markets. | 6 años |
Folke Per-Olof Wallström | M | 75 |
Swedish Orphan International Holding AB
Swedish Orphan International Holding AB Pharmaceuticals: MajorHealth Technology Swedish Orphan International Holding AB is an international group with its head office in Stockholm, Sweden. The original company was formed in 1988, taking as its starting point the US Orphan Drug Act of 1983. In 2004, the company was acquired by a consortium consisting of Investor Growth Capital, Skandia Investment and the management of Swedish Orphan International AB. The operating companies are Swedish Orphan International and its subsidiaries in Europe and Japan. The organizational structure is primarily based on a logistical perspective. In order to reach patients in emergency situations, regardless of where they are, it needs an extensive organization with strong local roots and the ability to see things in a larger perspective. The better and broader its partnerships, the more effectively the firm can work and the greater the synergies that it can achieve between the various markets. | 6 años |
Carl-Johan Spak | M | 68 | 12 años | |
Anders Olof Adolf Ekblom | M | 70 | 4 años | |
Peter Myrenfors | M | - |
Swedish Orphan International Holding AB
Swedish Orphan International Holding AB Pharmaceuticals: MajorHealth Technology Swedish Orphan International Holding AB is an international group with its head office in Stockholm, Sweden. The original company was formed in 1988, taking as its starting point the US Orphan Drug Act of 1983. In 2004, the company was acquired by a consortium consisting of Investor Growth Capital, Skandia Investment and the management of Swedish Orphan International AB. The operating companies are Swedish Orphan International and its subsidiaries in Europe and Japan. The organizational structure is primarily based on a logistical perspective. In order to reach patients in emergency situations, regardless of where they are, it needs an extensive organization with strong local roots and the ability to see things in a larger perspective. The better and broader its partnerships, the more effectively the firm can work and the greater the synergies that it can achieve between the various markets. | 3 años |
Kennet Rooth | M | 69 |
Swedish Orphan International Holding AB
Swedish Orphan International Holding AB Pharmaceuticals: MajorHealth Technology Swedish Orphan International Holding AB is an international group with its head office in Stockholm, Sweden. The original company was formed in 1988, taking as its starting point the US Orphan Drug Act of 1983. In 2004, the company was acquired by a consortium consisting of Investor Growth Capital, Skandia Investment and the management of Swedish Orphan International AB. The operating companies are Swedish Orphan International and its subsidiaries in Europe and Japan. The organizational structure is primarily based on a logistical perspective. In order to reach patients in emergency situations, regardless of where they are, it needs an extensive organization with strong local roots and the ability to see things in a larger perspective. The better and broader its partnerships, the more effectively the firm can work and the greater the synergies that it can achieve between the various markets. | 5 años |
Bertil Samuelsson | M | 74 | - | |
Kerstin Edung | F | - |
Swedish Orphan International Holding AB
Swedish Orphan International Holding AB Pharmaceuticals: MajorHealth Technology Swedish Orphan International Holding AB is an international group with its head office in Stockholm, Sweden. The original company was formed in 1988, taking as its starting point the US Orphan Drug Act of 1983. In 2004, the company was acquired by a consortium consisting of Investor Growth Capital, Skandia Investment and the management of Swedish Orphan International AB. The operating companies are Swedish Orphan International and its subsidiaries in Europe and Japan. The organizational structure is primarily based on a logistical perspective. In order to reach patients in emergency situations, regardless of where they are, it needs an extensive organization with strong local roots and the ability to see things in a larger perspective. The better and broader its partnerships, the more effectively the firm can work and the greater the synergies that it can achieve between the various markets. | - |
Håkan Wallin | M | 62 | 5 años | |
Claes E. Wilhelmsson | M | 85 |
Swedish Orphan International Holding AB
Swedish Orphan International Holding AB Pharmaceuticals: MajorHealth Technology Swedish Orphan International Holding AB is an international group with its head office in Stockholm, Sweden. The original company was formed in 1988, taking as its starting point the US Orphan Drug Act of 1983. In 2004, the company was acquired by a consortium consisting of Investor Growth Capital, Skandia Investment and the management of Swedish Orphan International AB. The operating companies are Swedish Orphan International and its subsidiaries in Europe and Japan. The organizational structure is primarily based on a logistical perspective. In order to reach patients in emergency situations, regardless of where they are, it needs an extensive organization with strong local roots and the ability to see things in a larger perspective. The better and broader its partnerships, the more effectively the firm can work and the greater the synergies that it can achieve between the various markets. | 6 años |
Gudrun Hörnquist | M | - |
Swedish Orphan International Holding AB
Swedish Orphan International Holding AB Pharmaceuticals: MajorHealth Technology Swedish Orphan International Holding AB is an international group with its head office in Stockholm, Sweden. The original company was formed in 1988, taking as its starting point the US Orphan Drug Act of 1983. In 2004, the company was acquired by a consortium consisting of Investor Growth Capital, Skandia Investment and the management of Swedish Orphan International AB. The operating companies are Swedish Orphan International and its subsidiaries in Europe and Japan. The organizational structure is primarily based on a logistical perspective. In order to reach patients in emergency situations, regardless of where they are, it needs an extensive organization with strong local roots and the ability to see things in a larger perspective. The better and broader its partnerships, the more effectively the firm can work and the greater the synergies that it can achieve between the various markets. | 15 años |
Bo Öberg | M | - | 1 años | |
Fredrik Lehmann | M | 48 |
Axelar AB
Axelar AB BiotechnologyHealth Technology Axelar AB operates as a biotechnology company. It aims to develop novel efficacious anti-cancer treatments. The company was founded by Erik Gustav Magnus Axelson and Lars Olov Larsson in 2003 and is headquartered in Solna, Sweden. | 1 años |
Jens D. Kristensen | M | 66 | - | |
Mattias Larsson | M | - |
Swedish Orphan International Holding AB
Swedish Orphan International Holding AB Pharmaceuticals: MajorHealth Technology Swedish Orphan International Holding AB is an international group with its head office in Stockholm, Sweden. The original company was formed in 1988, taking as its starting point the US Orphan Drug Act of 1983. In 2004, the company was acquired by a consortium consisting of Investor Growth Capital, Skandia Investment and the management of Swedish Orphan International AB. The operating companies are Swedish Orphan International and its subsidiaries in Europe and Japan. The organizational structure is primarily based on a logistical perspective. In order to reach patients in emergency situations, regardless of where they are, it needs an extensive organization with strong local roots and the ability to see things in a larger perspective. The better and broader its partnerships, the more effectively the firm can work and the greater the synergies that it can achieve between the various markets. | - |
Cecilia Schéele | F | - | 14 años |
Estadísticas
País | Relaciones | % del total |
---|---|---|
Suecia | 72 | 91.14% |
Finlandia | 7 | 8.86% |
Antigüedad de la relación
Activas
Pasados
Hombre
Mujer
Administradores
Ejecutivos
Origen de las relaciones
- Bolsa de valores
- Insiders
- Nils-Göran Pettersson
- Red Personal